Article Text

Download PDFPDF
Single heterozygous mutations in atp13a2 cause mitochondrial dysfunction
  1. Jin Sung Park1,2,
  2. Christine Klein3,
  3. Carolyn M Sue1,2
  1. 1Royal North Shore Hospital, Sydney, NSW, Australia
  2. 2Department of Neurogenetics, Kolling Institute, University of Sydney, St. Leonards
  3. 3Institute of Neurogenetics, University of Lübeck, Lübeck, Germany


Objectives Bi-allelic mutations in ATP13A2 have been associated with Kufor-Rakeb syndrome, an autosomal recessive juvenile-onset Parkinson’s disease (PD). Interestingly, several studies have reported the development of PD in single heterozygous ATP13A2 mutation (sHTZ-PK9) carriers, suggesting their role as a risk factor for PD. However, the pathogenicity of these mutations remained unexplored. To understand the role of these mutations in PD, therefore, we tested whether sHTZ-PK9 impairs cellular function associated with PD.

Methods We determined the extent of mitochondrial dysfunction in skin fibroblast lines derived from three single heterozygous ATP13A2 mutation sHTZ-PK9 carriers (one carrier harbouring c.3176T>G and two carriers with c.3057delC) and healthy controls (n=3). In addition, we also assessed possible alterations in Zn2+ metabolism.

Results The level of total ATP13A2 transcripts was lower in cells carrying the c.3057delC mutation in ATP13A2 compared with controls, while it was higher in cells carrying the c.3176T>G mutation with both wild-type and mutant transcripts elevated to a similar level. When mitochondrial oxygen consumption rate (OCR) was measured, sHTZ-PK9 cells showed a significant decrease in the maximal OCR. Furthermore, ATP production rate and mitochondrial membrane potential, as well as mitochondrial network interconnectivity, were also reduced in the sHTZ-PK9 cells, indicating mitochondrial dysfunction. However, the level of reactive oxygen species remained unchanged. In addition, sHTZ-PK9 cells showed decreased transcripts of zinc transporters and increased cytotoxicity to ZnCl2 treatment, suggesting Zn2+ dyshomeostasis, while the intracellular free Zn2+ levels were normal in sHTZ-PK9 cells.

Conclusions Our results indicate mitochondrial dysfunction in skin fibroblasts carrying single heterozygous ATP13A2 mutations despite a differential effect of the mutations on ATP13A2 expression. Given that impaired Zn2+ homeostasis is detected in sHTZ-PK9 cells, it is possible that altered Zn2+ metabolism underlies mitochondrial dysfunction. Collectively, these findings support that single heterozygous ATP13A2 mutations function as a risk factor for PD.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.